Pulmonx Co. (NASDAQ:LUNG) Insider Sells $30,726.20 in Stock

Pulmonx Co. (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 4,586 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total transaction of $30,726.20. Following the completion of the transaction, the insider now owns 295,433 shares in the company, valued at approximately $1,979,401.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Geoffrey Beran Rose also recently made the following trade(s):

• On Monday, June 24th, Geoffrey Beran Rose sold 1,184 shares of Pulmonx stock. The shares were sold at an average price of $6.16, for a total transaction of $7,293.44.

Pulmonx Stock Up 5.3 %

Shares of Pulmonx stock opened at $7.31 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84. The business has a 50-day moving average of $6.92 and a 200-day moving average of $7.82. The company has a market capitalization of $283.74 million, a PE ratio of -4.75 and a beta of 0.63.

Analyst Ratings Changes

LUNG has been the topic of several research reports. Canaccord Genuity Group raised their price objective on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company dropped their target price on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Finally, Lake Street Capital began coverage on Pulmonx in a report on Tuesday, June 4th. They issued a “buy” rating and a $12.00 price target for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

Institutional Investors Weigh In On Pulmonx

A number of hedge funds have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC purchased a new position in shares of Pulmonx during the 2nd quarter valued at approximately $477,000. Mackenzie Financial Corp acquired a new stake in Pulmonx in the second quarter valued at $102,000. Deerfield Management Company L.P. Series C boosted its stake in Pulmonx by 134.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 47,539 shares of the company’s stock valued at $301,000 after acquiring an additional 27,250 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Pulmonx during the 2nd quarter valued at $37,000. Finally, Squarepoint Ops LLC grew its holdings in Pulmonx by 261.2% during the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock worth $916,000 after acquiring an additional 104,432 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.